The Impacts of Alternative Alliance Partner Policies of Big Pharmaceutical Firms and Their Smaller Biotechnology Partner Firms: A System Dynamics Approach
by Moncrief, Kevin Warren, Ph.D., THE CLAREMONT GRADUATE UNIVERSITY, 2010, 472 pages; 3436592

Abstract:

Alliances between big pharmaceutical firms (BPF) and smaller biotechnology firms (BIOF) are increasing. The 20 largest BPF firms formed nearly 1,500 alliances with BIOFs between 1977 and 2002 (Lam 2004). Over half of the current 20 best-selling BPF prescription drugs were co-developed, co-marketed, or in-license with BIOF firms, accounting for 40 percent of BPF revenues (Lam 2004). However, sixty percent of drug discovery alliances fail to achieve expected results—half for non-technical reasons (Laroia and Krishnan 2005). Nonetheless, alliances are becoming more important for BPF firms because alliances help them to meet or exceed competitive growth rate projections.

This dissertation explores the effect of BPF firm management policies on creating and fostering alliances with partner firms. The study had main objectives. (1) Analyze the Patterns and Trends in BPF/BIOF Alliances. (2) Develop a Framework for Modeling the Alliances. (3) Test the Validity of the System Dynamics Model.

Study #1 was conducted based on 18 years of historical data on alliances for 3 large BPF firms: Johnson & Johnson, Pfizer, and Eli Lilly, ranked 1st, 2nd, and 10th in reported 2009 revenues. Analysis of alliance management data collected in Study #1 for the period 1993 through 2008 showed great similarity among the large BPF firms in their alliance selection practices. Of the 16 alliance deal attributes defining the alliances, the BIOF firm characteristics and BPF firm characteristics, 13 were similar. Study #1 showed that dynamic relationships exist among revenue growth, exploration alliances, exploitation alliance, R&D investments, and licensing royalties.

In Study #2, a framework for studying alliances was developed based on the results of Study #1. The framework was used to create the System Dynamics model. Furthermore, it is shown that the alliance agreements depend on the strength of the ties between the BPF and BIOF firms. The sensitivity analyses tested nine assertions (from Study #1) that involve revenue, exploration, exploitation, and strength of ties. The results validate the model.

 
AdviserPaul Gray
SchoolTHE CLAREMONT GRADUATE UNIVERSITY
SourceDAI/A 72-01, p. , Dec 2010
Source TypeDissertation
SubjectsManagement; Pharmaceutical sciences
Publication Number3436592
Adobe PDF Access the complete dissertation:
 

» Find an electronic copy at your library.
  Use the link below to access a full citation record of this graduate work:
  http://gateway.proquest.com/openurl%3furl_ver=Z39.88-2004%26res_dat=xri:pqdiss%26rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation%26rft_dat=xri:pqdiss:3436592
  If your library subscribes to the ProQuest Dissertations & Theses (PQDT) database, you may be entitled to a free electronic version of this graduate work. If not, you will have the option to purchase one, and access a 24 page preview for free (if available).

About ProQuest Dissertations & Theses
With over 2.3 million records, the ProQuest Dissertations & Theses (PQDT) database is the most comprehensive collection of dissertations and theses in the world. It is the database of record for graduate research.

The database includes citations of graduate works ranging from the first U.S. dissertation, accepted in 1861, to those accepted as recently as last semester. Of the 2.3 million graduate works included in the database, ProQuest offers more than 1.9 million in full text formats. Of those, over 860,000 are available in PDF format. More than 60,000 dissertations and theses are added to the database each year.

If you have questions, please feel free to visit the ProQuest Web site - http://www.proquest.com - or call ProQuest Hotline Customer Support at 1-800-521-3042.